Deleting Smad4 and PTEN genes in mice causes rapid, invasive stomach cancer.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
March 2009 in “The Journal of Urology” Shorter PSADT after prostate surgery is linked to higher risk of death.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
15 citations
,
January 2009 in “International Journal of Andrology” Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
29 citations
,
July 2013 in “The Journal of Sexual Medicine” Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
18 citations
,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
12 citations
,
August 2020 in “Annals of Oncology” Androgen deprivation therapy might be better for preventing COVID-19 than treating it.
11 citations
,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
11 citations
,
June 2020 in “Biomedicines” % free PSA and urinary markers help better identify prostate cancer.
9 citations
,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
9 citations
,
June 2018 in “Scientific Reports” People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.
8 citations
,
December 2016 in “Revista Medica De Chile” Finasteride can cause sexual dysfunction, sperm changes, and affect bone density and metabolism.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
7 citations
,
January 2016 in “British Journal of Cancer” Men with certain types of baldness at age 45 may have a higher risk of colon cancer and colorectal adenoma.
6 citations
,
May 2022 in “Research and reports in urology” Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.
4 citations
,
May 2013 in “Canadian Urological Association Journal” Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
1 citations
,
May 2021 in “Problemy e̊ndokrinologii” Androgen levels can increase at any age, affecting symptoms like acne, hair loss, and prostate size.
November 2025 in “Cancers” Men with male pattern baldness may have a slightly higher risk of prostate cancer.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
April 2024 in “Prostate international” Male pattern baldness does not cause an increased risk of prostate cancer.